Summary:
The aim of this study was to assess the results of hematopoietic stem cell transplantation (HSCT) in refractory Langerhans cell histiocytosis (LCH). Among 85 patients with LCH and hematological dysfunction diagnosed in France between 1987 and 2000, eight received HSCT in six institutions. Median age at diagnosis was 0.54 years. The median LCH activity score at diagnosis was 10 (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . All patients responded poorly to initial chemotherapy. At the time of HSCT, the median activity score was 16.5 (range 7-18). HSCT was autologous in three cases and allogeneic in five cases. The conditioning regimen consisted of TBI in two cases and chemotherapy alone in six cases. Conditioning had to be attenuated in two patients. All patients had persistent active disease after autologous HSCT, which was fatal in two cases and controlled by chemotherapy in one case. After allogeneic HSCT, two patients died from toxicity and three had complete responses; two patients had had no recurrences after 21 months and 7 years of follow-up, while the other patient relapsed and died from sepsis related to splenectomy. HSCT for refractory LCH can thus be highly toxic but can also achieve sustained disease control. Bone Marrow Transplantation (2003) 31, 1097-1103. doi:10.1038/sj.bmt.1704065 Keywords: Langerhans cell histiocytosis; bone marrow transplantation; multicenter study Langerhans cell histiocytosis (LCH) is a rare disease with variable clinical manifestations and prognosis. Patients with multisystem disease and organ dysfunction are usually treated with combination chemotherapy including vinblastine and steroids. The prognosis of patients with disease progression after a first course of chemotherapy is very poor, [1] [2] [3] and hematopoietic stem cell transplantation (HSCT) may be an option in such cases. 4 HSCT has been proposed for LCH in various clinical situations, including recurrent multifocal bone lesions, adult lung involvement, and refractory LCH in children. Based on a nationwide register, we collected information on all HSCT procedures performed for refractory LCH in France over a 13-year period.
Patients and methods

Enrollment
The diagnosis of LCH was based on the Histiocyte Society criteria, 5 that is, mainly morphological features and additional criteria such as CD1a expression or the presence of Birbeck granules on electron microscopy.
Patients with LCH were included in a computer database initially created for a retrospective study of LCH from 1983 to 1993. 3 Patients were enrolled prospectively from 1994 to 31 December 2001, and, after 1 April 1996, were enrolled in the Histiocyte Society LCH II trials. All 34 French pediatric hemato-oncology centers participated in this study. The French LCH database was crossed with the French transplant database to ensure exhaustive patient enrollment. Unique patient numbers (UPN) were attributed according to the inclusion sequence in the international database held in Vienna, Austria, where the first three digits represent the protocol era (210: retrospective; 140 LCH II protocol) while the last four digits represent the inclusion number.
Nine patients underwent HSCT during the study period. We excluded one patient from this analysis because of age at HSCT (34 years) and the indication (central nervous system LCH).
Data monitoring and follow-up. Data monitoring, based on the medical charts, was performed at each site. A disease activity score (Table 1) was calculated retrospectively, at diagnosis and immediately before HSCT, and the Karnofsky score was calculated retrospectively.
Statistical methods. Stata s version 7 software was used for all statistical analyses. Median follow-up was estimated by using Schemper's method. 6 The cutoff date for this analysis was 30 March 2002.
Description of patients and pre-HSCT status
Five male and three female patients were enrolled ( Table 2) . Median age at diagnosis was 0.54 years (range 0.2-1.5 years). At diagnosis, all but one of the patients had at least lung or liver involvement or hematological dysfunction.
Hematological dysfunction was present at diagnosis in six patients, and occurred later in two patients. The LCH activity score at diagnosis was 10 or more in five patients. Initial therapy combined vinblastine (at least four doses of 6 mg/m 2 ) and steroids (40 mg/m 2 ) in six patients. One patient received vinblastine (six pulses), steroids and VP16 (six pulses at 150 mg/m 2 ), and one patient received a combination of vincristine, prednisone and cyclophosphamide. All patients had a poor response to initial chemotherapy, with an increase in the activity score (if initially below 10) or stability of the score (if initially above 10). Various therapies were subsequently given, including VP16, and Ara-C in five cases, and cyclosporin A, antithymocyte globulin, 2 CDA and retinoic acid in one case. Splenectomy was performed in four patients, for hypersplenism in three cases and to reduce the tumor burden in one case. The activity score increased to 12 or more prior to HSCT in every case, and ranged from 7 to 18 at the time of HSCT (median 16.5). The median Karnofsky score at the time of HSCT was 30 (range 20-50).
Conditioning regimens and type of HSCT
The eight patients underwent HSCT a median of 18 months after diagnosis (range 7-21 months). The procedure was autologous in three cases; the donor was an HLA-matched sibling in four cases and an HLA-matched unrelated donor in one case ( Table 3 ). The total number of nucleated marrow cells infused ranged from 5.4 Â 10 8 to 7.1 Â 10 8 /kg in allogeneic procedures. For autologous HSCT, the graft was totally depleted of CD1a cells in case #2106095, and was not manipulated in the other two cases. Conditioning (Table 3) consisted of various chemotherapy-based regimens in six patients (busulfan and cyclophosphamide in three patients; busulfan, VP16 and cyclophosphamide in two patients; and busulfan and VP16 in one patient). In this last patient the dose of VP16 was reduced because of an allergic reaction. Conditioning was based on TBI in two cases: one patient received a single reduced dose of 2.18 Gy, while the other patient received standard TBI on three consecutive days (4 Gy/day) together with 60 mg/kg VP16.
GVHD prophylaxis
For the five recipients of allogeneic grafts, graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A in two cases, cyclosporin A and short-course methotrexate in one case, cyclosporin A and prednisone in one case, and cyclosporin A combined with mycophenolate mofetil in one case.
Results
Hematological recovery after HSCT
Hematological recovery failed and LCH remained active in one of the three patients who underwent autologous HSCT, and in one of the five patients who underwent allogeneic HSCT. In the other six patients, the median time required for granulocyte count to reach more than 1 Â 10 9 /l was 21 Table 1 LCH activity score applied in this study 
Survival, relapse and outcome
Five patients died, a median of 8 months after HSCT (1-23 months) . No factors associated with survival were identified, including the interval between LCH diagnosis and HSCT, the Karnofsky score and the LCH activity score prior to HSCT. Relapse occurred in four of the seven patients who survived more than 3 months, after a median of 2.5 months.
Outcome of autologous HSCT
Among the three patients who received autologous HSCT, the disease remained refractory in two cases, leading to death.
UPN #2106082 developed acute respiratory distress because of exacerbation of pulmonary LCH infiltration 15 days after transplantation; a relapse occurred 45 days after HSCT, with new bone lesions and cutaneous and gastrointestinal involvement but normal marrow aspirates. He did not respond to vinblastine, prednisone and VP16 and died 6 months after HSCT of acute respiratory distress caused by progressive lung disease.
The post transplantation course of patient UPN #1406369 was complicated by persistent high fever, massive hepatosplenomegaly, cholestasis, severe hypoalbuminemia, and ascites. Disease relapse was confirmed by skin biopsy, showing CD1a-positive LCH cells. He died from multiorgan failure 4 months after HSCT.
In the third patient who received autologous HSCT (UPN #2106095), the disease was transiently improved, but three relapses localized to bone and lung occurred. The first relapse was detected 3 months after HSCT. The disease was subsequently treated for 29 months with vinblastine and steroids. This patient is alive and disease-free 7 years after HSCT.
Outcome of allogeneic HSCT
Two of the five patients who received allogeneic HSCT died from toxicity, respectively, 32 days and 4 months after transplantation. This latter patient had late engraftment (2 months), mainly consisting of T lymphocytes, which was associated with acute GVH disease; he died from multiorgan failure with thrombocytopenic microangiopathy, with no evidence of LCH. Three patients had complete responses. Of note, two patients never relapsed, despite failure of engraftment in one (UPN #2106132).
In patient UPN #1406021, the post-transplantation course was complicated by intrapulmonary hemorrhage after 18 days, and Mycoplasma pericarditis after 107 days. At 6 months after HSCT, no LCH cells were found in marrow aspirates and the hepatomegaly had resolved, but bilateral pulmonary infiltrates persisted. At present, 21 
Discussion
We describe the outcome of HSCT in eight children with refractory LCH treated between 1988 and 2001. The patients were enrolled through a national LCH register comprising a total of 594 patients, 85 of whom had hematological dysfunction (transfusion requirements), and 24 of whom were considered refractory to initial chemotherapy. We focused this analysis on refractory patients with hematological dysfunction because their short-term outcome is known to be extremely poor.
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The use of HSCT is controversial in other situations, such as recurrent bone lesions, 4 lung or liver involvement, 4, 7, 8 and neurodegenerative lesions (one such patient was excluded from this study). In our database, refractory hematological dysfunction accounted for more than twothirds of deaths among patients with LCH. We used an objective-scoring system to assess LCH disease activity in all patients with hematological dysfunction. The results of HSCT have previously been reported in 17 LCH patients, none of whom were enrolled in nationwide surveys. Three publications describing multiple cases were single-center surveys. [8] [9] [10] Published data are summarized in Table 4 . Age at LCH diagnosis was below 2 years in nine cases, between 2 and 18 years in four cases and over 18 years in two cases. No details of liver and lung involvement were given in the first report, 4 but the disease was severe because of recurrent bone lesions. HSCT was performed 7.8 years after LCH onset. Clinical status was not described in two other patients. 9 The remaining 14 patients had organ dysfunction, consisting of liver involvement (nine patients), lung involvement (11 patients) or hematological involvement (9 patients); six patients had lung+liver+hematolo-gical involvement. Allogeneic transplantation was performed in 15 of the 17 cases, and various conditioning regimens were used. The 5-year survival rate calculated for all previously reported cases was 85% in children under 2 years of age with hematological dysfunction (n ¼ 8), compared to 37.5% in our survey. This discrepancy may be explained by a publication bias (underestimating negative results) or by the possibility that HSCT was performed in less severe situations than in our series. In our survey, as in the literature, disease manifestations were highly variable, as were chemotherapy regimens received prior to HSCT.
Prior chemotherapy must be taken into account when considering HSCT. Salvage therapy based on new agents such as 2 CDA, alone or in combination with Ara-C, is less toxic than HSCT and should be attempted first. However, it is noteworthy that one patient 11 out of the 17 so far reported, a child who received 2 CDA and aracytine with no response, was subsequently cured by cord-blood HSCT. This shows that HSCT can be useful for LCH that is refractory to alternative therapies.
Most patients are extremely poor by the time HSCT is considered, as reflected by low Karnofsky scores and the need for nutritional, anti-infectious and hematological support. This poor status can contraindicate HSCT. Indeed, in our survey only a third of eligible patients were actually transplanted. Poor general health may contribute to pulmonary and multiorgan toxicity, and led to reduced conditioning in two of our patients. Greinix, Kinugawa and Egeler reported six toxic deaths among 10 patients. [8] [9] [10] The 'window of opportunity' for HSCT in LCH is therefore narrow.
Two of the three patients who received autologous HSCT failed to respond, while the third was transiently improved but subsequently relapsed (the relapse was controlled by chemotherapy). Relapse has been reported in one out of two previous autologous HSCT procedures. 8 Among the five patients who received allogeneic HSCT, two died of toxicity within 4 months, while LCH was controlled in the other three patients. One of these three patients relapsed and died from sepsis related to splenectomy, and two are free of disease 21 months and 7 years after transplantation. In the literature, the 11 patients who survived for more than 3 months were disease-free, and the incidence of severe GVHD was relatively low.
Thus, although HSCT for refractory LCH can be a hazardous procedure, the optimal timing and modalities of which are unclear, allogeneic HSCT is a valid option for some patients and warrants further evaluation.
